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Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality and of loss
of disability-adjusted life years worldwide. It often is accompanied by the presence of
comorbidity.
Objectives
To systematically review the influence of COPD comorbidity on generic health-related qual-
ity of life (HRQoL).
Methods
A systematic review approach was used to search the databases Pubmed, Embase and
Cochrane Library for studies evaluating the influence of comorbidity on HRQoL in COPD.
Identified studies were analyzed according to study characteristics, generic HRQoL mea-
surement instrument, COPD severity and comorbid HRQoL impact. Studies using only non-
generic instruments were excluded.
Results
25 studies met the selection criteria. Seven studies utilized the EQ-5D, six studies each
used the SF-36 or SF-12. The remaining studies used one of six other instruments each.
Utilities were calculated by four EQ-5D studies and one 15D study. Patient populations cov-
ered both early and advanced stages of COPD and ranged from populations with mostly
stage 1 and 2 to studies with patients classified mainly stage 3 and 4. Evidence was mainly
created for cardiovascular disease, depression and anxiety as well as diabetes but also for
quantitative comorbid associations. Strong evidence is pointing towards the significant neg-
ative association of depression and anxiety on reduced HRQoL in COPD patients. While all
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studies found the occurrence of specific comorbidities to decrease HRQoL in COPD
patients, the orders of magnitude diverged. Due to different patient populations, different
measurement tools and different concomitant diseases the study heterogeneity was high.
Conclusions
Facilitating multimorbid intervention guidance, instead of applying a parsimony based single
disease paradigm, should constitute an important goal for improving HRQoL of COPD
patients in research and in clinical practice.
Background
Generating over 76 million disability adjusted life-years (DALYs) globally in 2010, chronic
obstructive pulmonary disease (COPD) surpassed road-traffic injuries, and when focusing on
the US alone, it was the second highest contributor of DALYs after ischemic heart disease [1].
Smoking is the main risk factor for developing COPD [2], while all hallmarks of ageing [3]
seem to influence its progression [4]. The pathogenesis of COPD is multidimensional [5, 6].
Inflammation, airway remodeling and fibrosis as well as tissue destruction seem to play consti-
tuting roles for the usually progressive nature of the disease [7]. There is currently no cure for
COPD and the need for disease modifying treatments is still unmet [8] although possible tar-
gets seem promising [9, 10]. Comorbidity is common for COPD [11] and COPD patients use
disproportional amounts of health services for the treatment of their comorbid conditions [12–
16]. However, comorbidities are often considered as exclusion criteria for participants of
COPD studies or are disregarded in respective evaluations [17]. In a study [18] from Italy in
2014, around 80% of COPD patients were treated by protocols derived from randomized clini-
cal trials, for which they would not have been eligible to participate in. By doing so, a reduc-
tionist paradigm regarding disease classification [19, 20], largely based on end-stage
appearance of symptoms, is compounded by strict study eligibility criteria. Taken together, this
likely fails to account for different patho-phenotypes and thus mirrors a partial failure to reflect
clinical reality. Health-related quality of life (HRQoL), next to survival and costs, is one impor-
tant measure for cost-effectiveness of interventions. However, controversies about clinical
implementation of HRQoL are still present [21]. The importance of improving clinical man-
agement and thus HRQoL of COPD patients afflicted by comorbidity has been object of inves-
tigation by several studies [22–25]. Therefore, evaluating comorbid influences on HRQoL in
COPD could help to unravel disease constellations of interest for patients, physicians and pay-
ers. The aim of this review is to aggregate and summarize evidence for the influence of comor-
bidities on generic HRQoL in COPD.
Methods
Measuring HRQoL
HRQoL can be measured by different instruments. Some of these instruments are disease spe-
cific (e.g. St. George's Respiratory Questionnaire (SGRQ) [26]), while others are generic, mean-
ing they can be compared among different fields of indication. Disease-specific instruments
were excluded from this review. The rationale for this decision is rooted in the fact that dis-
ease-specific instruments were not designed to evaluate comorbid influences unless the effects
are expressed by the index disease and can therefore be measured by the disease-specific
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instrument. For example, the widely used SGRQ was designed to measure the effects of airflow
limitation on HRQoL [26] but it was not intended to measure effects unrelated to airflow limi-
tation. In contrast, generic instruments were designed to measure HRQoL irrespective of mul-
timorbidity and way of expression. Still, it could be interesting to evaluate the effect of different
comorbidities on various measures of disease-specific outcome. This is beyond the scope of
this review, however. Examples for well accepted and widely used generic instruments include
the EuroQol five-dimension questionnaire (EQ-5D) [27], which, inter alia, was used in major
COPD studies like the TOwards a Revolution in COPD Health (TORCH)-trial [28]. The EQ-
5D consists of 5 descriptive questions (self-classifier) and a valuation by a visual analogue scale
(VAS) labelled EQ-5D-VAS score. The results for the 5 dimensions can be transformed into
utilities, which are needed for cost-effectiveness analysis. In order to derive population based
utilities for different health states the most widely used method is time-trade-off (TTO) [29],
typically surveyed in representative samples of the general population. The TTO procedure
elicits the time in perfect health which respondents consider equal to a given time in a health
state, with the relation of both rendering the health state’s value. Other important generic
instruments include but are not limited to the 36-Item Short Form Health Survey (SF-36) [30],
the 12-Item Short Form Health Survey (SF-12) [31], two instruments with pre-defined sum-
mary scores such as average across the items of one dimension, and the 15D questionnaire
(15D) [32]. The SF-36 is made up of 36 items, which are grouped into 8 subdomains. For each
subdomain, a score between 0 (worst) and 100 (best) can be reached. The SF-12 is a short ver-
sion of the SF-36 and contains 12 items. These 12 items reproduce at least 90% variance of the
physical component summary score (PCS) and the mental component summary score (MCS)
from SF-36 [31]. The 15D is a 15-dimensional self-administered generic instrument which can
be used a single and profile index score measure, also rendering utility measurement. Citations
for other, less used instruments are provided in this review and can be used to gather more
respective information. Beyond clinical assessment, utility measures of HRQoL provide a key
effect measure in economic evaluation studies.
Search strategy and exclusion criteria
The respective literature search was performed on May 5th 2015. Studies only using disease-
specific instruments were excluded. The publication date was not restricted. Pubmed was
searched using the following terms: (((((copd[MeSH Terms]) OR copd) OR obstructive lung
disease) OR obstructive pulmonary disease)) AND (((("Quality of Life"[Mesh]) OR quality of
life) OR health status) OR "Health Status"[Mesh]) AND (("Comorbidity"[Mesh]) OR
comorbid)
This resulted in 1125 hits. Embase was searched by ((copd OR obstructive lung disease OR
obstructive pulmonary disease) AND comorbid AND (quality of life OR health status)) NOT
SU =MEDLINE and was restricted for journal articles. 629 results were found. 3 records [33–
35] were identified by hand search. In addition to this, the Cochrane Library was searched for
respective reviews (COPD AND comorbid AND quality of life) but none were found. Com-
bining the results lead to 1757 studies in total. After removing duplicates, 1528 studies
remained. The language filter (English, German) was implemented and studies using non-
generic HRQoL instruments were removed. Studies that did not deliver comorbid based
results, were also excluded. The PRISMA flow diagram [36] was used to depict the study selec-
tion process (Fig 1). The PRISMA checklist is annexed as supplementary data (see S1 File.) as
well as a list (see S2 File.) with studies and their respective reason for exclusion.
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Data extraction
Basic population characteristics, generic HRQoL measurement instrument, severity of COPD,
prevalence of comorbidities and the comorbid association regarding generic HRQoL were
extracted from all selected studies under review. Valuation methods for index instruments like
the EQ-5D and the 15D instrument were actively investigated for unless clearly stated in the
respective study. Comorbid generic HRQoL data was the main point of interest. Tabular aggre-
gation of homogenous and sorted data for single comorbidities was attempted but failed due to
heterogeneity issues among studies. Thus, study-per-study subsumption based on utilized
HRQoL instrument was incorporated. They were separated into instruments valuated by
patients (e.g. EQ-5D-VAS only), instruments valuated by population (e.g. EQ-5D-5L and 15D)
and measures with pre-defined summary score (e.g. SF-36, SF-12). This improves clarity for
different stakeholders. Medical doctors, for example, will prefer patient valuated results due to
their relevance for clinical practice. In order to reduce possible bias [37] of this review, non-sig-
nificant associations of comorbidities and HRQoL were also reported. The discussion part is
structured based on comorbidity.
Results
Of the 25 studies, 16 were published in 2010 or later, while 6 were from 2014 alone. Study ori-
gin was diverse, including countries from different parts of the world. The mostly used generic
instruments for measuring HRQoL were the EQ-5D in seven studies [38, 33, 39–43], the SF-12
in six studies [44–49] and SF-36 in six studies [34, 35, 50–53] as well. Table 1A shows a sum-
mary of basic study characteristics, COPD severity and comorbidity impact based on HRQoL
valued by patients. Table 1B shows summary measures utilizing population valuation and
Table 1C shows respective parameters for studies using pre-defined summary measure
instruments.
Fig 1. Study selection process.
doi:10.1371/journal.pone.0132670.g001
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Table 1. Studies on comorbidity impact.
Part a. HRQoL instruments based on patient valuation
Study Country Gender (%) Prevalence of comorbidities in Results
Sample size Mean age (± SD)z COPD patients and controls (if available)
Source Severity of COPD
HRQoL instrument, valuation,
analysis type
Boros et al. 2012
[38]
- Poland - N(C) 8,537 - Self-report Linear regression influence of
significant predictorson health state
(measured by VAS):
- Survey (patients across
Poland)
- Female 36% - Heart failure 21.7%
- Age 64.41 ± 9.86 - Ischemic heart disease 19.9% - Heart failure: β = -0.313
- EQ-5D-VAS (regression of
single CDs)
- GOLD Stage I 15.7% - Other cardiovascular: β = -0.026
- GOLD Stage II 53.9% - Cardiac arrhythmias 8.6% - Endocrine/diabetes: β = -0.029
- GOLD Stage III 26.5% - Other cardiovascular 32.1% - Number of comorbidities: β = -0.139
- GOLD Stage IV 3.8% - Endocrine disorders 10.2%
- Alimentary tract disorders 12.3%
Frei et al. 2014
[39]
- Switzerland, Netherlands - N(C) 408 - Assessment by study nurse or physician
interviews and verified by medication usage
Coefficients of predictors for outcome
(FT):
- Female 42.9% - Depression (HADS11): -9.00
(-13.52, -4.48)
- Survey (primary care patients
fromICE COLD ERIC)
- Age 67.3 ± 10.0 - Anxiety (HADS11): -5.53, (-10.25,
-0.81)
- GOLD Group A 41.9% - Peripheral artery disease: -5.02,
(-10.64, 0.60)




- GOLD Group C 13.5% - Hypertension 42.2% - Symptomatic heart disease: -3.81
(-7.23, -0.39)- GOLD Group D 22.6% - Arthrosis 29.4%
- Obesity 20.3%
- Symptomatic heart disease 20.3%
Cleland et al.
2007 [33]
- UK - N(C) 110 - Self-report Spearman’s rank correlation (rho)
between EQ-5DVAS and HADS
anxiety: -0.49 (p<0.001)
- Survey (three neighbouring
practices in Aberdeen)
Female 48.2% - Depression (HADS11) 20.8%
- Age 66.76 ± 9.60 Spearman’s rank correlation (rho)
between EQ-5DVAS and HADS
depression: -0.54 (p<0.001)
- GOLD Stage I 25.5% - Anxiety(HADS11) 32.7%
- GOLD Stage II 56.4%
- EQ-5D-VAS (rank correlation) - GOLD Stage III 13.6%
- GOLD Stage IV 4.5%
Part b. HRQoL instruments based on population valuation
Koskela et al.
2014 [54]
- Finland - N(C-15D) 731 - Medical records 15D group: Adjusted ORs for risk factors of low
15D score (0.65):- Pulmonary clinicsof Helsinki
and Turku University Hospital
- Female 36%




- Diabetes: 2.12 (p = 0.03)
- FEV1: > 80%
pred.
















43.5% - Atrial Fibrillation 30 (y) 468
(n)
- Psychiatric disease: 4.65 (p<0.001)
- FEV1: < 40%
pred.
18.5% - Cancer 44 (y) 687
(n)
- Alcohol abuse: 2.33 (p = 0.007)




- Hypertension (not significant)




- Cancer (not significant)




- Spain - N(C) 4,552 - Face-to-Face interview Correlation between EQ-5D scores
and patient variables by Pearson’s r:- INSEPOC (pulmonologists
and family doctors)
- Female 16.7%
- Age 67.1±10 - CCI (mean) 1.8±1.5 - CCI: -0.330
- FEV1: % pred. 48.3±21 - HADS anxiety (HADS11): -0.602
- HADS depression (HADS11):
-0.674
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Table 1. (Continued)
Sundh et al. 2015
[42]
- Sweden - N(C) 373 - Physician interview Association between HRQoL response
and comorbidity:- Secondary care respiratory
units
- Female 55.8% - Cardiovascular 59.8%
- Age (female) 70.5±7.58 - Diabetes 10.7% - Musculoskeletal disease: -0.08
(p = 0.006)
- EQ-5D (TTO; multiple linear
regression)
- Age (male) 72.2±8.11 - Musculoskeletal 24.1% [Index]
- GOLD stage III 69.4% - Osteoporosis 27.6% - Depression (interview): -0.10
(p = 0.002)
- GOLD stage IV 30.6% - Depression (interview) 16.6% [Index]




- Spain - N(C) 713 - Self-report OR for EQ-5D utility association5) with
depression:- DEPREPOC (multicenter) - Female: 17% - CCI (mean) 1.4±1.4
- Age 68.3±9.3 - Depression (mild to severe: BDI5) 74.6% Univariate: 0.92 (p<0.05)
- EQ-5D (TTO) - FEV1 52.1±17.3% Multivariate: 0.94 (p<0.05)





Mölken et al. 2006
[41]
- 13 countries - N(C) 1,235 - Diagnosis questionnaire4) Higher number of comorbidities and
higher
- UPLIFT trial - Female 27% CCI score were not associated with
worse
- EQ-5D (TTO; multivariate
linear regression)
- Age 64.5±8.4 - Patients with CD 85.7% EQ-5D VAS score. The impact of
number of CDs on EQ-5D utility was
highly significant (p<0.001) but small
(coefficient around -0.01).
- GOLD Stage II 50.7% - CCI (mean) 0.51
- GOLD Stage III 41.8% - Vascular 48%






- USA - N(C) 100 - Medical records Univariate regression r (correlation):
- Outpatient practices - Female 53% - Myocardial infarct 15% - CCI: -0.05 (p = 0.62)
- Age 62.2±10.5 - Cancer 14%
- Documented FEV1<30% - FEV1 (mean) 24.4±3.9 - Ulcer disease 9%
- Stroke 7%
- MILQ (univariate correlation) - Diabetes 6%
- CCI (median) 1
Part c. HRQoL instruments with pre-defined summary measures
Miguel-Diez et al.
2010 [47]
- Spain - N(C) 7,620 - Self-report The presence of heart disease in
patients with COPD was associated
with worse scores for the physical and
mental component of the SF-12.
- EPIDEPOC (primary care
setting)
- N(C+HD) 1,770 - Blood hypertension 40.8% |
64.3%
- Female(C) 25% - Hypercholesterolemia 37.7% |
44.5%
- Female(C+HD) 21.1% - Diabetes 12.2% |
29.5%
- SF-12 (multivariate logistic
regression)
- Age(C) ± 9.56 - Gastroduodenal ulcer 13.7% |
19.2%












- FEV1: <40% pred. 8.9% | 22.3%
(Continued)
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Table 1. (Continued)
Putcha et al. 2013
[56]
- USA - N(<3 CDs) 232 - Self-report OR for worse health status with all
independently associated CDs




- N(3 CDs) 611 - Selected comorbidities:
- Female (<3 CD) 52.1%
- Female (3 CD) 55.5% - Prostate disease 63.6% - CHF: 3.07 (p<0.001)
- Age (<3 CD |
3CD)
61.4 | 64.0 - Depressive symptoms (by medication) 42.4% - CHD: 1.47 (p = 0.085)
- HRQOL-4 (linear and logistic
regression)
- Arthritis: 1.67 (p = 0.012)
- Severity of COPD Not stated - CHF 15.1% - Diabetes: 1.63 (p = 0.046)
- Diabetes 13.9% - Depression: 1.39 (p = 0.155)
- CD count: - Prostate disease: 1.63 (p = 0.045)
0 CD 4.3% For every CD increase by one, the
odds of worse self-rated health
increased by 43%.
More than 2 CDs 83.6%
Janson et al. 2013
[45]






- BOLD Initiative Female1) 41.0%-
54.0%
- SF-12 (regressionof single
CDs)
Age1) 55.2 ± 10.8 to
64.9 ± 12.2
- Heart disease 12.6–22.9% 1) -1.5 (-2.6, -0.46) -0.12 (-1.3, 1.1)
- Hypertension 24.4–39.4% 1) -0.23 (-1.1, 0.46) -0.51 (-1.5, 0.46)
- No COPD 81,1% - Diabetes 7.2–11.7% 1) -2.0 (-3.6, -0.53) -0.69 (-2.4, 1.0)
- GOLD Stage I 8,6% - Stroke 2.6–5.7% 1) -3.0 (-5.1, -1.0) +0.82 (-1.4, 3.1)
- GOLD Stage II 7,9%
- GOLD Stage III 2,1%
- GOLD Stage IV 0,3%
Van Manen et al.
2001 [53]
- Netherlands - N(C) 163 - Self-report Presence of three or more CDs was
stronglyrelated to all domains of
HRQoL, while the respective eight
most common individual CDs
(locomotive disease, hypertension,
heart disease, insomnia, gastric ulcus,
sinusitis, cancer, dizziness), except
insomnia, were not.
- 28 general practices - Female 28.2% - Comorbidity³) 72.3%
- Age 66.8±9.8 - Locomotive disease 37.9%
- SF-36 (linear regression) - FEV1: <50%
pred.
36.8% - Hypertension 20.1%
- FEV1: 50–70%
pred.




23.3% - Ulcer 9.8%
Wacker et al.
2014 [44]
- Germany - N(C) 101 - Self-report Linear mixed models showed a
negative association for heart failure
(-4.9 points), myocardial infarct (-3.3),
stroke (-5.6), cancer (-3.2), diabetes
(-1.7) regarding PCS-but only a
significant negative associationfor
heart failure (-2.8), stroke (-4.0) and
diabetes (-2.1) regarding MCS-12.
- KORA - N(NoC) 1,220 - Cancer 4.95% | 4.7%
- SF-12 (linear mixed
regression models)




- Diabetes 1.98% | 3.9%
- Age | 51.6 - Myocardial infarction 0% | 1.8%
- GOLD stage I 60% - Heart failure 1.98% | 1.1%
- GOLD stage II 40% - Stroke 0.99% | 1.1%
- GOLD stage III
+IV
1%
Kil et al. 2010 [34] - South Korea - N(C) 91 - Self-report based on Depressed patients had significantly
(p < 0.05) lower scores in the four
following dimensions:
- Korea University Ansan
Hospital
- Female 14.3% BDI
- Age ± 8.2 - Depression (BDI16) 15.4%
- SF-36 (unadjustedcomparison
of group means)
- GOLD Stage I 14.2% - Physical functioning
- GOLD Stage II 51.7% - Bodily pain
- GOLD Stage III 29.7% - Vitality
- GOLD Stage IV 4.4% - General Health
Results for the other dimensions were
insignificant
(Continued)
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Table 1. (Continued)
Ng et al. 2009 [48] - Singapore - N(C) 189 - Self-report and verification by drug package Adjusted OR for association of
depressive symptoms with self-rated
health among patients with COPD
(adjusted for COPD severity, gender,
age, education, smoking, comorbidity,
BADL disability, dyspnea):




- Female(NoC) 63.2% - Depressive symptoms 22.8% |
12.4%
- Age(C | NoC) (GDS5)
55–64 37.6% |
50.5%

















- FEV1: <50% pred. 9.5%
Bentsen et al.
2014 [57]
- Norway - N(C) 100 - Self-report Unstandardizied betas for association
between parameter and generic QoL:- Outpatient clinic - Female 49 - No. of comorbidities 1.67
- QOLS (multiple linear
regression)
- Age 66.1±18.3 - Anxiety (HADS8) 5.9±3.9 - No. of comorbidities -0.466 (p<0.581)
- GOLD Stage I 0 - Depression (HADS8) 4.5±3.7 - Anxiety -0.320 (p<0.381)
- GOLD Stage II 44 - Depression -2.200 (p<0.001)
- GOLD Stage III 43
- GOLD Stage IV 13
Cully et al. 2006
[52]
- USA - N(C) 179 - Self-report Subscales (significant factors
associated with worse health status):
Physical functioning (BAI,
comorbidity); Role Physical (BDI),
Bodily Pain (BAI); General Health
(BAI), Vitality (BDI, BAI); Social
Functioning (BAI, BDI); Role-
Emotional (BAI, BDI); Mental Health
(BAI,BDI)
- Veterans Medical Center - Female 5% - BAI (16) 24.6±9.3
- Age 65.8±10.5 - BDI (20) 22.5±9.4








- USA - N(C) 495 - Diagnosis Multiple linear regression coefficients
for PFS and PCS (adjusted for
baseline characteristics):
- Routine data Erie and Niagara
Counties, NY
- Female 45.2% questionnaire
- Age 64.15±9.97 - Anemia 7.47%
- GOLD Stage I 0.6% - Myocardial Infarction 11.31% - β (PFS_Diabetes) = -0.13 (p<0.0001)
- SF-36 (multiple linear
regression)
- GOLD Stage II 87.7% - Renal Disease 2.02% - β (PCS_Diabetes) = -0.07 (p = 0.02)
- GOLD Stage III 11.1% - Diabetes 16.57% Causal relationship for anemia and
HRQoL not established. History of
myocardial infarct and renal disease
not significant.
- GOLD Stage IV 1.2%
Rascon-Aguilar
2011 [51]
- USA - N(C) 86 - Self-report Comparison of SF-36 means between
COPD+GERD and COPD only:- Pulmonary clinic University of
Florida/Jacksonv.
- Female(GERD) 41% - Hypertension 43.8 | 47.1
- Female(nGERD) 46.3% - Coronary artery disease 28.1 | 9.4 Bodily pain: 51.7 | 66.7 (p<0.02)
- Age(GERD) 66.0±9.9 Mental health: 60.5 | 71.3 (p<0.03)










- Diabetes 12.5 | 13.21
- Depression 12.5 | 13.21
Xiang et al. 2014
[49]
- Hong Kong - N(C) 142 - Face-to-Face interview MCS and PCS scores were not
significantly associated with number of
illnesses but werea significant
predictor for SGRQ QoL.
- 1 hospital - N(Controls) 218
- COPD medical records - Female(C) 16.9 - GDS(C) 4.7±4.1
- Female(Control) 24.8 - GDS(Control) 2.8±3.1
- SF-12 (multiple linear
regression)
- Age(C) 73.9±6.2 - No. of comorbidities (C) 3.0±1.7
- Age(Control) 75.0±6.0
- GOLD Stage I 6.3% - No. of comorbidities (Control) 1.9±1.3
- GOLD Stage II 15.5%
- GOLD Stage III 45.8%
- GOLD Stage IV 32.4%
(Continued)
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Table 1. (Continued)
Lopez Varela
et al. 2013 [46]
- Latin America - N(C) 759 - Self-report An association between increased
comorbidity score (unweighted) and
deteriorating general health status was
observed. Of the evaluated
comorbidities, diabetes had the
strongest effect on HRQoL detoriation.
- Multi-stage cluster sampling in
five Latin American cities
- N(NoC) 4,555 - Heart disease 13.7%| 12.7%
- Female(C) 47.7% - Hypertension 37.2% |
33.7%
- Female(NoC) 62.6% - CVA 3.2% | 2.1%
- Age(C)60 33.5% - Cardiovascular 41.5% |
38.8%
- Age(NoC)60 28.7% - Diabetes 8.4% | 9.9%
- SF-12 (comparison of means) - FEV1: <70% pred. 14.3% - Peptic ulcer 31.8% |
29.9%
- Lung cancer 1.1% | 0.1%
- Asthma 22.8% |
10.5%
Van Manen et al.
2003 [50]
- Netherlands - N(C) 148 - Self-report Linear regression influence of
dichotomous comorbidity on SF-36
score (p<0.05):
- General practices - N(NoC) 364 - 1–2 chronic diseases 52.7% |
51,9%
- SF-36 (dichotomous linear
regression)
- Female(C) 30.4% - 3–4 chronic diseases 15.5% | 8,8% Physical functioning: β = -12
- Female(NoC) 57.7% - 5 chronic diseases 4.1% | 2,2% Role functioning physical: β = -24.7
- Age(C) 60 77.03% Social functioning: β = -10.8
- Age(NoC) 60 69.51% Mental health: β = -8.0
- FEV1: <50% pred. 37.2% Role functioning emotional: β = -16.2
- FEV1: 50–70%
pred.
38.5% Vitality: β = -14.0
Bodily pain: β = -16.3
- FEV1: 70–80%
pred.
24.3% General health: β = -13.0
Shavro et al. 2012
[58]
- India - N(C) 58 - Unknown No association between comorbid
illness and HRQoL. [Unknown cause.
Small sample size? Aspects of Indian
culture?]
- 1 hospital - Female 7% - Gastric disease 21%
- WHOQOL-BREF - Age 62.4±7.8 - Hypertension 19%
- GOLD Stage I 1.7% - Diabetes Mellitus 17%
- GOLD Stage II 79.3% - Heart disease 16%
- GOLD Stage III 19% - 0 comorbidities 34%
- 1 comorbidity 29%
- 2 comorbidities 24%
- 3 comorbidities 12%
Wijnhoven et al.
2003 [59]
- Netherlands - N(C) 161 - Face-to-Face interview Adjusted significant ORs for poor
HRQoL (NHP total score):- General practices - Female 44.7%
- NHP (logistic - regression) - Age 61.0±10.3 - No CD 46.6% - >1 CD: 3.22
- FEV1: % pred. 60.7±15.0 - One CD 30.4% - Presence of musculoskeletal
disorders: 2.52- More than one CD 23.0%
- Musculoskeletal 27.3% Not significant: 1 CD; Cardiac disease;
Hypertension- Cardiac 19.3%
- Hypertension 17.4%
1): depending on COPD status and severity grade
3): The presence of comorbidity was only calculated for patients who filled out the respective questionnaire
4): Patients were asked if they had a physician diagnosis for respective comorbidities
5): OR<1 implicates lower chance for depression when EQ-5D score increases; BAI: Beck Anxiety Inventory; BDI: Beck Depression Inventory; C: COPD;
CCI: Charlson comorbidity index; CD: Comorbid disease; CHF: Congestive heart failure; CHR: Coronary heart disease; ERS: European Respiratory
Society; GERD: Gastroesophageal reflux disease; GOLD: Global Initiative for Chronic Obstructive Lung Disease; HADS: Hospital Anxiety and Depression
Scale; HD: Heart Disease; MCS: Mental component summary score; MILQ: Multidimensional Index of Life Quality; NHP: Nottingham Health Profile; OR:
Odds ratio; PCS: Physical component summary score; PFS: Physical Functioning Scale; PMR: Patient medical record; Post-BD: post-bronchodilator;
SGRQ: St George's Respiratory Questionnaire; TTO: Time-trade-off
doi:10.1371/journal.pone.0132670.t001
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All but one EQ-5D study reported using the EQ-5D-3L version with a 3-level distinction of
problems reported. Miravitlles et al. 2014 [43] did neither report the used version, nor the used
value sets. Three studies used patient’s VAS valuation [33, 39, 38]. Three studies used value sets
based on time-trade-off valuations by a general population, taken from a UK [60], US [61] and
Spanish [62] setting. Instruments used by a single study each are the self-administered
15-dimension 15D [32], the 35-item Multidimensional Index of Life Quality (MILQ) [63], the
16-item Quality of Life Scale (QOLS) [64], the 26-itemWorld Health Organization Quality of
Life-BREF (WHOQOL-BREF) [65], the 4-item Health Related Quality of Life-4 (HRQOL-4)
[66] and the 38-item Nottingham Health Profile (NHP) [67]. They were utilized by one study
[54, 56, 59, 58, 57, 43, 55] each. Valuation of the 15D instrument was done by population-
based multiattributive utility theory [32]. Besides EQ-5D and 15D, no index instruments were
used. References regarding the validation of the used instrument for COPD as well as respective
comorbidity were only given by one study [51]. Sample sizes ranged from 58 [58] to 11,985
[45] COPD patients. The prevailing gender was male in the majority of studies and was even as
high as 95% in a study [52] with veterans and 93% in a study [58] from India. The average age
was above 60 years in all studies respectively. The severity of COPD was assessed in nearly all
studies. Classification of COPD severity was mostly based on GOLD criteria but other cut-off
points for predicted forced expiratory volume in 1 second (FEV1) were also used for classifica-
tion of patients. Some studies only stated average FEV1 values and one study [56] did not state
severity classification at all. The majority of patients had an average FEV1 predicted of around
and/or above 50% but heterogeneity was high. Studies [42, 55, 49] with mainly severe to very
severe cases of COPD were also present. Seven studies [50, 48, 56, 52, 49, 57, 58] assessed the
number of comorbidities per patient. The majority of patients seem to be afflicted by around
two or more comorbidities. All studies reported some form of association between specific
comorbidity and worse HRQoL. However, the comorbid influence as well as its significance
differed among studies. The most prevalent evaluated diseases were cardiovascular disease
(CVD), which is a far reaching umbrella term for diseases of the heart and/or blood vessels, as
well as depression and anxiety. Ten studies [38, 39, 45, 54, 47, 56, 44, 59, 53, 46] looked at the
influence of cardiovascular disease on HRQoL. A negative association was stated in seven of
the studies, while three studies [54, 59, 53] did not find a significant association. The non-sig-
nificance was mentioned by the authors but not explained through specific reasons. Regarding
depression, only one [56] of the ten studies [33, 39, 34, 40, 48, 56, 42, 43, 57, 54] did not find a
significant negative association with HRQoL. The EQ-5D index, based on TTO, was associated
with depression in three studies [40, 42, 43]. In another study [54], psychiatric disease had an
adjusted odds ratio (OR) of 4.65 for low 15D score. Ng et al. 2009 [48] calculated an adjusted
OR of 4.17 for depression and low self-rated health measured by SF-12. Two additional studies
[52, 57] report a significant negative association for depression and HRQoL measured by SF-
36 and QOLS. A comparable picture emerges for anxiety, which had a non-significant associa-
tion in only one study [57]. Diabetes was associated with worse HRQoL in all respective studies
[38, 45, 54, 35, 46, 56, 44]. Two studies [59, 42], using EQ-5D index and NHP, also found a
negative influence of musculoskeletal disease on HRQoL, the former study stating a value of
-0.08 (p = 0.006) based on multiple linear regression for the association between presence of
musculoskeletal disease and EQ-5D index. The presence of comorbidity, irrespective of type,
was also associated with lower HRQoL scores in six [46, 56, 59, 50, 40, 53] out of ten studies
and was significantly associated with worse physical functioning in one study [52]. Presence of
more than one comorbidity resulted in an adjusted OR of 3.22 for poor HRQoL, measured by
NHP [59]. Rutten-van Mölken et al. 2006 [41] stated, that a higher number of comorbidities
and higher Charlson Comorbidity Index (CCI) score was not associated with lower EQ-
5D-VAS score, while the impact on EQ-5D index was significant but only small. Blindermann
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et al. 2009 also found CCI not to be associated with worse MILQ scores but considered this to
be rooted in the low CCI median of 1 they started with. Three studies [49, 58, 57] did not find
any significant association for number of comorbidities and worse generic HRQoL. Other sig-
nificant negative associations were found for insomnia [53], alcohol abuse [54], arthritis [56],
gastroesophageal reflux disease (GERD) [51] and osteoporosis [42].
Discussion
The results clearly show that specific concomitant diseases in COPD were associated with
worse generic HRQoL, irrespective of utilized instrument. However, the degree of HRQoL
impact varied and some studies delivered contradicting results.
Comorbid CVD
One of the comorbidities with significant influence on HRQoL was CVD. Boros et al. 2012 [38]
calculated a standardized linear regression coefficient of -0.313 for the association of the EQ-
5D-VAS and presence of heart failure in COPD. This transforms into a 15 point reduction on
the VAS scale (according to author correspondence). This standardized coefficient is around
10 times higher than standardized EQ-5D-VAS coefficients for other cardiovascular diseases
excluding ischemic heart disease (-0.145), in the same study. Frei et al. 2014 [39] stated a EQ-
5D-VAS predictor of -4.6 and -3.8 for cerebrovascular and symptomatic heart disease respec-
tively, while Wacker et al. 2014 [44] found a significant negative association for heart failure as
well as stroke and the physical and mental component summary among patients with COPD.
This receives additional importance because observational data indicates, that COPD patients
are at increased risk for developing CVD [68]. Three [59, 54, 53] out of ten respective studies
[38, 53, 39, 54, 45, 47, 44, 56, 59, 46] did not find a significant association between comorbid
CVD and HRQoL. Van Manen et al. 2001 [53] explain the lack of significant association for
heart disease by pointing to the relative low number of patients with the disease (n = 25) in
their study. Koskela et al. 2014 [54] did not state a reason for the lack of association and Wijn-
hoven et al. 2003 [59] only found a negative association for heart disease and asthma but not
for COPD. They point towards differences in disease characteristics as possible explanation. In
addition to this, CVD is a far reaching umbrella term for diseases of the heart and circulation
and this may explain inconsistencies among results since different patient populations may be
affected by different cardiovascular disorders and different severity grades. This general limita-
tion is mentioned by Sundh et al. 2015 [42].
Comorbid depression and anxiety
Other comorbidities with strong association for worse HRQoL were depression and anxiety.
11 studies evaluated its comorbid influence on HRQoL. Cut-off points for being depressed
were 11 for the HADS in three studies. Interestingly, the only study [57] using a lower
HADS cut-off point of8 stated a non-significant (p<0.381) HRQoL association for anxiety
but not depression. The non-significance may be explained by the lower cut-off point and
hence, a lower severity grade of overall anxiety in this patient population. This is confirmed by
looking at the HADS-A mean scores. While Bentsen et al. [57] stated a HADS-A mean of 5.9
(SD: 3.9), the other two studies [39] stated higher means of 9 (SD = 4.2) for females, 7.2 (SD: 4)
for males or an average of 7 (SD: na). Table 2 shows an overview of respective results among
studies using the EQ-5D instrument. It became apparent that depression ranked first among
comorbidities with significant association for worse HRQoL in all four studies. Consequen-
tially, in all three studies [33, 39, 40] where a comparison was possible, depression had always
a stronger influence on worse HRQoL than anxiety. Naberan et al. 2012 [40] calculated an
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r value of -0.674 (-0.602) for the correlation of HADS depression (anxiety) and the EQ-5D
index score and found this to be the best correlation in their study. In another study [39],
depression was associated with a reduction of EQ-5D-VAS score by around 9 points. Interest-
ing from a practical perspective, Cleland et al. 2007 [33] stated the possible use of the EQ-
5D-VAS as quick and easy screening tool for patient’s mental health in COPD. This procedure
would be supported by the results of Frei et al. 2014 [39], who also found a strong association
for depression and low EQ-5D-VAS score. Irrespective of these two studies, other authors
point towards usage of health status measures as indicators for depression in COPD as well
[69]. A problem regarding evaluation of index based influence of comorbidity on HRQoL in
COPD is that depression and anxiety, two disorders which showed a strong influence on
HRQoL, are completely missing from indices like the CCI. Therefore exclusively using these
indices will likely fail to deliver a complete picture of comorbid associations with HRQoL. In
general, we would therefore agree with Frei et al. 2014 [39], who stated, that comorbidity based
indices which predict mortality are not designed to evaluate HRQoL status. They may serve as
indicator but attention has to be paid when evaluating their results.
Comorbid diabetes
Diabetes was associated with worse HRQoL in all respective studies and among many
different instruments including EQ-5D-VAS [38], SF-12 [45, 46, 44], SF-36 [35], 15D [54] and
HRQOL-4 [56]. In addition to this finding, comorbid diabetes seems to worsen the prognosis
[70] and lengthen the hospital stays of COPD patients with acute exacerbations due to immune
dysfunction [71].
Comorbid musculoskeletal disease
Musculoskeletal disease also was significantly associated with worse HRQoL in two studies [42,
59]. The association for presence of the disease and EQ-5D index score was -0.08 (p = 0.006)
[42]. Interestingly, muscle wasting in COPD seems also to be a better predictor for mortality,
than BMI [72, 73]. Muscle wasting is connected to fatigue and reduced activity [74]. Since
mobility, activity and self-care are three dimensions of the EQ-5D a drop of HRQoL scores in
patients who suffer from muscle wasting is not very surprising.
Number of comorbidities
Three [57, 49, 58] out of eleven studies [38, 41, 52, 53, 50, 46, 57, 58, 56, 59, 49] did not find a
significant association between number of comorbidities and worse generic HRQoL. Shavro
et al. 2012 [58] mention this finding to be surprising and possible rooted in the small sample
size (n = 58) and/or aspects of Indian culture. A connection between comorbidities and worse
scores for the WHOQOL-BREF or SGRQ scores was not found in their study. Xiang et al. 2014
Table 2. Results and ranks of depression and anxiety for comorbid influences on HRQoL by studies using EQ-5D.
Result type Result D Result A Rank D Rank A Total range
Cleland et al. 2007 [33] Spearman’s rho EQ-5D-VAS -0.54 -0.49 1 (2) 2 (2) -0.49 to -0.54
Frei et al. 2014 [39] Regression coefficient EQ-5D-VAS -9.00 -5.53 1 (5) 2 (5) -3.81 to -9.00
Naberan et al. 2012 [40] Pearson’s r EQ-5D-Index -0.67 -0.60 1 (3) 2 (3) -0.33 to 0.67
Sundh et al. 2015 [42] Regression coefficient EQ-5D-Index -0.10 n.a. 1 (3) n.a. -0.07 to -0.10
Total range refers to the range of results among comorbidities with significant influence on HRQoL in the respective study
D: depression; A: anxiety; (): number of available ranks
doi:10.1371/journal.pone.0132670.t002
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[49] found number of comorbidities to be associated with worse SGRQ results but not with SF-
12. Bentsen et al. 2014 [57] found the same relation for QOLS and SF-12. It seems counter-
intuitive that disease specific instruments react more sensitive to the presence of comorbidity
compared to generic instruments, unless the respective comorbidity has a significant effect on
COPD symptoms. Unfortunately, since only number of comorbidities were evaluated by both
studies, specific conclusions for individual diseases can’t be drawn and the statistical power is
low to begin with. However, advantages of using disease-specific and generic instruments
together have been stated before [75]. Conducting a review on the comorbid influences on
HRQoL measured by disease-specific instruments, would thus be interesting from a research
perspective.
Comparing comorbid costs and HRQoL
When considering the effect of comorbidities on the cost-effectiveness of COPD intervention,
next to HRQoL, the cost impact is relevant. A previous systematic review found comorbidities
in COPD patients to be associated with significant excess cost [76]. However, the impact of
comorbidities on cost of COPD patients cannot directly be compared with that of HRQoL: The
instruments used for measurement of HRQoL were diverse, as were statistical measures of
comorbidity impact. Furthermore, control groups were lacking in many HRQoL studies. In
contrast, most of the HRQoL studies measured stage of COPD while this information was
sparse in cost studies. A simultaneous view upon cost and HRQoL impact of comorbidities is
thus hindered by possible differences in study patients, and by diverging methods. Simulta-
neous study of both dimensions in individual patients is needed to provide a comprehensive
view of comorbidity impact.
Limitations and strength of this review
Limitations of this review include the non-active search for studies which consider COPD as
the comorbidity and other diseases as index disease. However, by doing so, an increase in
already high study heterogeneity was likely prevented to some degree. The present heterogene-
ity is rooted in the evaluation of different patient populations and comorbidities but also in the
use of different HRQoL instruments, different value-sets and different outcome measurements,
which decrease comparability even further. Moreover, when population-based value sets are
being used to aggregate HRQoL, applying an experience-based approach rather than one based
on hypothetical health states as in three studies [42, 41, 40] could help to increase physician
acceptance of HRQoL results, shifting the focus to actual patient experience [77]. Last but not
least the severity of comorbidities was not assessed in the studies under review. Thus, the influ-
ence of comorbid severity on HRQoL remains unclear.
Strength of this review is the aggregation of generic evidence on HRQoL pertaining the
comorbid influences in COPD and illustrating evidence in aggregated and comprehended
form. Over 1700 studies were filtered and screened and to our knowledge this is the first review
evaluating comorbid effects on generic HRQoL. Furthermore, using multiplicative methods,
which showed superior performance compared to minimum or additive methods when trying
to incorporate selective comorbid burden into health state utilities [78–80] could allow creating
decision analytical COPD models by the aggregated data, which resemble clinical reality to a
higher degree.
Conclusion
Comorbidities in COPD are significantly associated with worse HRQoL among all used instru-
ments. The majority of evidence was generated for CVD, depression and anxiety as well as
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diabetes but other comorbid conditions like musculoskeletal disease, have a worsening influ-
ence on HRQoL in COPD as well. The sole presence of quantitative comorbidity was also con-
nected to lower HRQoL. These results should be considered in clinical practice and in studies
evaluating interventions in respective patient populations. Not considering the HRQoL impact
of existing comorbidity might lead to inappropriate clinical management and to biases in eval-
uation studies. It became apparent that facilitating multimorbid intervention guidance, instead
of applying a parsimony based single disease paradigm, constitutes an important current and
future goal for patient management in COPD.
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